Lefitolimod - MOLOGEN

Drug Profile

Lefitolimod - MOLOGEN

Alternative Names: MGN-1703

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mologen
  • Developer Aarhus Universitetshospital; Mologen; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; DNA
  • Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Small cell lung cancer
  • Phase I/II HIV-1 infections
  • Phase I Solid tumours
  • Preclinical Lymphoma

Most Recent Events

  • 04 Mar 2018 Immunogenicity and efficacy data from the phase Ib/IIa TEACH trial HIV-1 infections presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI-2018)
  • 13 Feb 2018 Lefitolimod licensed to ONCOLOGIE in China, Hong Kong, Macau, Taiwan and Singapore
  • 13 Feb 2018 MOLOGEN and ONCOLOGIE agree to co-develop lefitolimod in World for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top